Janux Therapeutics remains a hold, as JANX007 has a potential comeback opportunity, but declining response rates temper enthusiasm. I rate JANX stock as Hold.
2026-11-10. The following slide deck was published by Janux Therapeutics, Inc.
Janux Therapeutics earnings surprise and stock reaction The latest quarter was a catalyst. Janux Therapeutics (JANX) reported a narrower net loss and a smaller loss per share than a year ago, while revenue exceeded analyst expectations. Investors have reacted quickly to the earnings surprise, with a 1 day share price return of 9.78% lifting Janux Therapeutics to US$17.63. A 90 day share price return of 11.23% and a 3 year total shareholder return near 2x suggest longer term momentum, which...
Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline. This trial brings fresh attention to Janux Therapeutics’ prostate cancer platform, highlighting how the company is expanding its precision oncology approach into a difficult-to-treat setting. We’ll now examine how progress in this metastatic castration-resistant prostate...
Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the near term, with a 1-month share price return down 9.6% and a 7-day move down 1.75%, even as the 90-day share price return is up 6.36% and the year-to-date share price return stands at 19.41%. Over a...
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
SAN DIEGO, September 14, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
This is the newest page. Registered accounts read further back.